The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis-Reference-Cited by-同舟云学术

The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis

Published:2023-03-24 Issue:4 Volume:7 Page:
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:

Author:

Bossen Lars,Lau Tobias Stemann,Nielsen Mette Bak,Nielsen Marlene Christina,Andersen Astrid Højmark,Ott Peter,Becker Sabine,Glerup Henning,Svenningsen Lise,Eivindson Martin,Kornerup Linda,Kjeldsen Niels Bjørndal,Neumann Anders,Møller Holger Jon,Jepsen Peter,Grønbæk Henning

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Reference47 articles.

1. Primary biliary cirrhosis;Carey;Lancet,2015

2. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis;J Hepatol,2017

3. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis;Lleo;Hepatology,2010

4. The immunobiology and pathophysiology of primary biliary cirrhosis;Hirschfield;Annu Rev Pathol,2013

5. Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms;Tsuneyama;J Med Invest,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives;Frontiers in Pharmacology;2024-03-21

2. The treatment of primary biliary cholangitis: from shadow to light;Therapeutic Advances in Gastroenterology;2024-01